Loading organizations...
§ Private Profile · Boston, MA, USA
Healthcare technology and diagnostics company developing rapid point-of-care testing for infectious diseases like chlamydia and gonorrhea.
Based in Cambridge, Massachusetts, Binx Health is a healthcare technology company that develops rapid point-of-care molecular diagnostic testing platforms for infectious diseases. The organization's primary product is the FDA-cleared binx io platform, which delivers rapid diagnostic test results for conditions such as chlamydia and gonorrhea in approximately thirty minutes. Operating with a dedicated team of 28 employees, the enterprise generates an estimated $20.8 million in annual revenue and has secured $65 million in total funding across equity and debt financing. Binx Health is backed by a syndicate of institutional investors including Hildred Capital, EQT Life Sciences, and Alta Life Sciences. The company recently sold its consumer at-home testing division to digital health firm imaware to focus exclusively on its core enterprise and clinical partnerships. Binx Health was originally founded in 2017 by Jeffrey Luber.
Binx Health has raised $279.1M across 7 funding rounds.
Binx Health has raised $279.1M in total across 7 funding rounds.
binx health is a healthcare technology and diagnostics company that develops point-of-care (POC) molecular testing platforms, primarily the binx io system, which delivers FDA-cleared, CLIA-waived results for chlamydia and gonorrhea in about 30 minutes from urine or vaginal swab samples.[1][3][6] It serves clinicians in retail clinics, urgent care, primary care, supermarkets, and other non-lab settings, solving the problem of delayed central lab testing (days-long waits) by enabling single-visit test-and-treat workflows that improve patient convenience, adherence, and antibiotic stewardship.[2][3][4][6] The company targets large patient populations through partnerships with healthcare providers, urgent care networks like WellStreet, and initiatives for population health, with established reimbursement and national expansion momentum evidenced by partnerships (e.g., Mark Cuban Cost Plus Drug Company), studies with Mass General Hospital, and a reagent rental program launched amid rising STI rates.[6]
Originally offering both POC and at-home consumer testing, binx sold its consumer division to imaware in an undisclosed deal, retaining focus on its high-growth POC molecular platform after generating tens of millions in revenue from millions of tests since 2017.[2] Backed by investors like Johnson & Johnson Innovation, Novartis Venture Fund, and others, binx operates globally from Boston, MA, and Bath, UK, with 51-200 employees and 45 patents in molecular biology and biotech.[1][5]
binx health emerged from a focus on revolutionizing routine STI testing, with its consumer division founded in 2017 by Jeff Luber, who served as CEO of that unit.[2] The company built proprietary desktop PCR-based platforms to shift testing from slow central labs to on-demand POC and at-home options, addressing gaps in convenient care where people live, work, and shop.[1][4] Early traction came from developing the binx io platform—the first FDA-cleared, CLIA-waived POC system for chlamydia/gonorrhea in both sexes—securing investors like Novartis Venture Fund, LSP, BB Biotech, and strategic partners such as Consort Medical (for cartridge manufacturing) and Wondfo Biotech.[1][3]
Pivotal moments include 2021 recognition on CB Insights' Digital Health 150 list in Screening, Monitoring, and Diagnostics, and the 2022-2025 national rollout of binx io amid surging STIs, including a reagent rental program and Alabama self-collection kits.[4][6] In a strategic shift, binx divested its consumer testing business to imaware, allowing focus on POC growth while imaware scales at-home offerings.[2]
binx health rides the point-of-care diagnostics trend in digital health, accelerating from pandemic-driven decentralization to routine STI management amid WHO-reported surges in infections.[4][6] Timing aligns with rising demand for convenient, equitable care—overwhelmed labs, patient no-shows, and antimicrobial resistance—positioned by flexible POC tech that fits retail/urgent care models.[3][6] Market forces like reimbursement codes, urgent care growth, and telehealth integration favor binx, as seen in CB Insights' 2021 Digital Health 150 inclusion among 11,000+ nominees.[4][5]
It influences the ecosystem by enabling partners to expand reach, reduce unnecessary visits, and improve outcomes (e.g., Mass General study on stewardship), pushing molecular diagnostics beyond labs into everyday settings and competing with imaging/neurophysiology tools via cost-effective, rapid STI focus.[5][6]
binx health's POC-centric pivot post-consumer divestiture positions it for accelerated growth in a $multi-billion diagnostics market, with national rollout, partnerships, and STI crisis tailwinds driving adoption.[2][6] Expect expansion into additional multiplex tests (beyond chlamydia/gonorrhea), deeper urgent care/pharmacy penetration, and international scaling from UK base, shaped by trends like AI-enhanced workflows and value-based care.[1][6] Its influence could evolve by setting POC standards for infectious diseases, reducing healthcare burdens and inspiring hybrid at-home/clinic models—redefining convenient care as promised from day one.[3][4]
Binx Health has raised $279.1M in total across 7 funding rounds.
Binx Health's investors include Hildred Capital Management, Earlybird Venture Capital, EQT Life Sciences, OrbiMed, LSP, Scott Moonly, Tuan Huynh, Andrew Goldman, Johnson & Johnson Innovation, Parian Global, HealthCap, BB Biotech Ventures.
Binx Health has raised $279.1M across 7 funding rounds. Most recently, it raised $65.0M Series F in April 2024.